Compare Apple Inc (AAPL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs IDEXX Laboratories, Inc. — how do they compare? Apple Inc trades at $300.92 (market cap $4.45T), while IDEXX Laboratories, Inc. trades at $571.28 (market cap $46.22B). The key difference: Apple Inc is far larger — about 96.3× IDEXX Laboratories, Inc.'s market cap, and Apple Inc pays a 0.35% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| AAPL | IDXX | |
|---|---|---|
Market Cap | $4.45T | $46.22B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $766.68 |
52-Week Low | $224.90 | $526.44 |
Enterprise Value | $4.47T | $47.12B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and near-term support at $306. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Analyst consensus is bullish with a $337.63 price target, though recent news highlights union disputes and potential Q3 earnings pressure.
Outlook remains positive driven by AI opportunities and a massive device ecosystem, but risks include weaker iPhone sales, regulatory scrutiny, and union tensions. The stock offers growth potential with solid cash flow, yet investors should weigh near-term headwinds against long-term strengths.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
